UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Portfolio Pulse from Vandana Singh
UnitedHealth Group will remove AbbVie's Humira from its preferred reimbursement lists in 2025, opting for lower-cost biosimilars. This follows similar moves by Cigna and CVS Health. Despite competition, AbbVie retains a dominant market share for Humira.
September 11, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Humira will be removed from UnitedHealth's preferred lists in 2025, but it retains a strong market share despite biosimilar competition.
The removal of Humira from UnitedHealth's lists could negatively impact AbbVie's market share and revenues, although it currently retains a strong position.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 85
NEUTRAL IMPACT
Pfizer's biosimilar alternatives to Humira face competition but contribute to the growing market.
Pfizer's biosimilars are part of the competitive landscape, but the impact is neutral as the market adjusts.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
POSITIVE IMPACT
Amgen's Amjevita is among the biosimilars covered by UnitedHealth, potentially increasing its market presence.
Amgen's Amjevita being covered by UnitedHealth could enhance its market presence as a biosimilar alternative to Humira.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Cigna will also remove Humira from its lists in 2025, following a similar strategy to UnitedHealth and CVS Health.
Cigna's decision to remove Humira aligns with industry trends, potentially benefiting from cost savings.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
CVS Health's Caremark unit previously removed Humira, leading to a swift shift to biosimilars.
CVS Health's early move to remove Humira has set a precedent, potentially benefiting from early adoption of biosimilars.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
UnitedHealth will remove Humira from its preferred lists in 2025, opting for biosimilars. This aligns with industry trends to cut costs.
UnitedHealth's decision to replace Humira with biosimilars is part of a cost-cutting trend in the industry. This move could positively impact UNH's financials by reducing drug costs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90